.png){kind=icon}
.png){kind=icon}
Return
Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects
.png){kind=icon}
PRE
AI
R
X
Q
H
K
Z
DOI：10.1016/j.canlet.2026.218753.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• ADCs bypass, not reverse, multidrug resistance—succeeding where inhibitors failed. • Cleavable linkers drive bystander killing that overcomes tumor antigen heterogeneity. • T-DXd benefit extends from HER2-ultralow through HER2-positive disease. • ABCB1/ABCG2 polymorphisms govern ADC payload retention, efficacy, and toxicity. • Pooled T-DXd PFS HR 0.47 (HER2 continuum); 11.4% ILD across deruxtecan-payload ADCs.
Journal
IF:
10.1
Papers:
1.7W
Citations:
4.3W
Organization
Cited Papers